Stock search

Ticker or company name

Compare stocks

Market: US

  • ABTAbbott Laboratories

Add stock

Ticker or company

Summary

ABT
Abbott Laboratories
$107,45Down −0,99%
Year: Down −16%
33/100Ratio would not consider buying
Open stock page

Verdict

ABT has 5 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckABT2 ✓ 2 — 5 ✕
P/E vs its history40,0
P/E vs industry40,0
Forward P/E18,1
Revenue growth, YoY+10,0%
EPS growth, YoY−66,2%
Net margin9,7%
Net debt / EBITDA3,1
Free cash flow$6,76 bn
Share count over a year−0,7%
Cash runwayn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterABTTTMIndustry medianTTM
P/E TTM ↓40,025,1
Forward P/E ↓18,116,2
PEG ↓4,72,2
P/S TTM ↓3,92,2
EV/EBITDA ↓23,917,3
P/FCF ↓27,819,5

Price, %

  • ABTn/a

Returns

Best WorstNo mark — in between

PeriodABT
1 yearn/a
3 yearsn/a
5 yearsn/a
All timen/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

ABT
Share of “buy”79%
Beat the forecast1 of 4
Average “surprise”−0,1%
Insiders over 12 monthssales $43,5 m

Details are on each stock page.